Jari Räsänen

Dr. Jari Räsänen

1. Department of Cardiothoracic Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 2. Faculty of Medicine, University of Helsinki, Helsinki, Finland.
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Annals of Surgery
Verified
Journal Article
Closed access
HSHenner M. Schmidt
Henner M. Schmidt
SGSuzanne S. Gisbertz
Suzanne S. Gisbertz
JMJohnny Moons
Johnny Moons
IRIoannis Rouvelas
Ioannis Rouvelas
JKJuha Kauppi
Juha Kauppi
CGChristian A. Gutschow
Christian A. Gutschow
To define “best possible” outcomes in total minimally invasive transthoracic esophagectomy (ttMIE). TtMIE, performed by experts in patients with low comorbidity, may serve as a benchmark procedure for esophagectomy. From a cohort of 1057 ttMIE, performed over a 5-year period in 13 high-volume centers for esophageal surgery, we selected a study group of 334 patients (31.6%) that fulfilled criteria of low comorbidity (American Society of Anesthesiologists score ≤2, WHO/ECOG score ≤1, age ≤65 years, body mass index 19–29 kg/m2). Endpoints included postoperative morbidity measured by the Clavien-Dindo classification and the comprehensive complication index. Benchmark values were defined as the 75th percentile of the median outcome parameters of the participating centers to represent best achievable results. Benchmark patients were predominantly male (82.9%) with a median age of 58 years (53–62). High intrathoracic (Ivor Lewis) and cervical esophagogastrostomy (McKeown) were performed in 188 (56.3%) and 146 (43.7%) patients, respectively. Median (IQR) ICU and hospital stay was 0 (0–2) and 12 (9–18) days, respectively. 56.0% of patients developed at least 1 complication, and 26.9% experienced major morbidity (≥grade III), mostly related to pulmonary complications (25.7%), anastomotic leakage (15.9%), and cardiac events (13.5%). Benchmark values at 30 days after hospital discharge were ≤55.7% and ≤30.8% for overall and major complications, ≤18.0% for readmission, ≤3.1% for positive resection margins, and ≥23 for lymph node yield. Benchmarks at 30 and 90 days were ≤1.0% and ≤4.6% for mortality, and ≤40.8 and ≤42.8 for the comprehensive complication index, respectively. This outcome analysis of patients with low comorbidity undergoing ttMIE may serve as a reference to evaluate surgical performance in major esophageal resection.

1 September 2003 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
JRJari Räsänen
Jari Räsänen
ESEero I. T. Sihvo
Eero I. T. Sihvo
MKM. Juhani Knuuti
M. Juhani Knuuti
HMHeikki R. I. Minn
Heikki R. I. Minn
MLMarkku E. S. Luostarinen
Markku E. S. Luostarinen
JSJarmo A. Salo
Jarmo A. Salo

1 October 2016 in Diseases of the Esophagus
Verified
Journal Article
Closed access
PDF file
TRT. W. Rice
T. W. Rice
CAC. Apperson-Hansen
C. Apperson-Hansen
LDL. M. DiPaola
L. M. DiPaola
MSM. E. Semple
M. E. Semple
TLT. E. M. R. Lerut
T. E. M. R. Lerut
EBE. H. Blackstone
E. H. Blackstone

1 February 2009 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
ESEero I. Sihvo
Eero I. Sihvo
JSJarmo A. Salo
Jarmo A. Salo
JRJari Räsänen
Jari Räsänen
TRTuomo K. Rantanen
Tuomo K. Rantanen

4 July 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
EHEliza Hagens
Eliza Hagens
Mark I. van Berge HenegouwenMark I. van Berge Henegouwen
Mark I. van Berge Henegouwen
JSJohanna W. van Sandick
Johanna W. van Sandick
MCMiguel A. Cuesta
Miguel A. Cuesta
DPDonald L. van der Peet
Donald L. van der Peet
SGSuzanne S. Gisbertz
Suzanne S. Gisbertz
An important parameter for survival in patients with esophageal carcinoma is lymph node status. The distribution of lymph node metastases depends on tumor characteristics such as tumor location, histology, invasion depth, and on neoadjuvant treatment. The exact distribution is unknown. Neoadjuvant treatment and surgical strategy depends on the distribution pattern of nodal metastases but consensus on the extent of lymphadenectomy has not been reached. The aim of this study is to determine the distribution of lymph node metastases in patients with resectable esophageal or gastro-esophageal junction carcinoma in whom a transthoracic esophagectomy with a 2- or 3-field lymphadenectomy is performed. This can be the foundation for a uniform worldwide staging system and establishment of the optimal surgical strategy for esophageal cancer patients. The TIGER study is an international observational cohort study with 50 participating centers. Patients with a resectable esophageal or gastro-esophageal junction carcinoma in whom a transthoracic esophagectomy with a 2- or 3-field lymphadenectomy is performed in participating centers will be included. All lymph node stations will be excised and separately individually analyzed by pathological examination. The aim is to include 5000 patients. The primary endpoint is the distribution of lymph node metastases in esophageal and esophago-gastric junction carcinoma specimens following transthoracic esophagectomy with at least 2-field lymphadenectomy in relation to tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy and (disease free) survival. The TIGER study will provide a roadmap of the location of lymph node metastases in relation to tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy and survival. Patient-tailored treatment can be developed based on these results, such as the optimal radiation field and extent of lymphadenectomy based on the primary tumor characteristics. NCT03222895 , date of registration: July 19th, 2017.

29 January 2021 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
POPia Osterlund
Pia Osterlund
TSTapio Salminen
Tapio Salminen
LSLeena-Maija Soveri
Leena-Maija Soveri
RKRaija Kallio
Raija Kallio
IKIlmo Kellokumpu
Ilmo Kellokumpu
HIHelena Isoniemi
Helena Isoniemi
Resection of colorectal cancer (CRC) metastases provides good survival but is probably underused in real-world practice. A prospective Finnish nationwide study enrolled treatable metastatic CRC patients. The intervention was the assessment of resectability upfront and twice during first-line therapy by the multidisciplinary team (MDT) at Helsinki tertiary referral centre. The primary outcome was resection rates and survival. In 2012–2018, 1086 patients were included. Median follow-up was 58 months. Multiple metastatic sites were present in 500 (46%) patients at baseline and in 820 (76%) during disease trajectory. In MDT assessments, 447 (41%) were classified as resectable, 310 (29%) upfront and 137 (18%) after conversion therapy. Six-hundred and ninety curative intent resections or local ablative therapies (LAT) were performed in 399 patients (89% of 447 resectable). Multiple metastasectomies for multisite or later developing metastases were performed in 148 (37%) patients. Overall, 414 liver, 112 lung, 57 peritoneal, and 107 other metastasectomies were performed. Median OS was 80·4 months in R0/1-resected (HR 0·15; CI95% 0·12–0·19), 39·1 months in R2-resected/LAT (0·39; 0·29–0·53) patients, and 20·8 months in patients treated with “systemic therapy alone” (reference), with 5-year OS rates of 66%, 40%, and 6%, respectively. Repeated centralized MDT assessment in real-world metastatic CRC patients generates high resectability (41%) and resection rates (37%) with impressive survival, even when multisite metastases are present or develop later. The funders had no role in the study design, analysis, and interpretation of the data or writing of this report.